公司资料
Nutriband 股价、新闻与催化剂
- 股票代码:
- NTRB
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.36 USD (-2.13%)
收盘价
最后更新: 2026年10月1日
43.2M USD
市值
股价为何变动
最新监测到的公司动态为“Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders”。相应的收盘价反应尚未产生。
公司概览
Transdermal Pharmaceutical Company
Nutriband develops transdermal products and provides contract manufacturing services. Its strategy combines near-term manufacturing revenue with proprietary abuse-deterrent patch technology.
AVERSA Abuse-Deterrent Platform
AVERSA incorporates aversive agents into transdermal systems to discourage chewing, extraction, or other misuse. The platform is designed for potent drugs that benefit from continuous delivery but carry abuse risk.
AVERSA Fentanyl
The lead proprietary program applies AVERSA technology to a fentanyl patch. Nutriband is developing the product through the 505(b)(2) pathway with the goal of retaining analgesic delivery while adding abuse deterrence.
Contract Manufacturing Operations
Through Pocono Pharmaceutical, the company develops and manufactures topical and transdermal products for third parties. Services include formulation, coating, converting, packaging, and production of consumer and pharmaceutical patches.
Partner-Supported Development
Nutriband works with external manufacturers, development specialists, and regulatory advisers, including Kindeva for AVERSA Fentanyl. This model gives the company access to commercial-scale transdermal expertise without building every capability internally.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。